Glucagon Receptor Antagonist LGD-6972 Significantly Lowers HbA1c and Is Well Tolerated after 12-Week Treatment in Patients with Type 2 Diabetes Mellitus (T2DM) on Metformin

被引：2

作者：

Pettus, Jeremy

Vajda, Eric G.

Pipkin, James

Williamson, Gretchen

Zangmeister, Miriam A.

Li, Yong-Xi

Henry, Robert R.

D'Alessio, David

Frias, Juan P.

Zhi, Lin

Marschke, Keith

机构：

来源：

DIABETES | 2018年 / 67卷

关键词：

D O I：

10.2337/db18-73-OR

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：2

共 50 条

[21] Dapagliflozin (DAPA) Reduces HbA1c in Asian Patients with T2DM after Metformin (MET) Failure
Yang, Wenying
Han, Ping
Liu, Beijing
Mansfield, Traci
T'Joen, Caroline L.
Iqbal, Nayyar
Ptaszynska, Agata
DIABETES, 2014, 63 : A279 - A279
[22] The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus
Forst, T.
Uhlig-Laske, B.
Ring, A.
Ritzhaupt, A.
Graefe-Mody, U.
Dugi, K. A.
DIABETES OBESITY & METABOLISM, 2011, 13 (06): : 542 - 550
[23] Sitagliptin added to ongoing treatment with metformin improved glycemic control and was well tolerated in Japanese patients with type 2 diabetes (T2DM)
Kadowaki, Takashi
Tajima, Naoko
Odawara, Masato
Nishii, Mikio
Nonaka, Kenji
Stein, Peter P.
DIABETES, 2008, 57 : A589 - A590
[24] Effect of Iron Deficiency Anaemia on HbA1c levels in a cohort of patients with Type 2 diabetes mellitus (T2DM) in Sri Lanka
Kariyawasan, Chitranga
Dissanayaka, Champika
Balasuriya, Thushara
Ranatunga, Charith
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 184 - 185
[25] Sustained reduction in HbA1c during one-year treatment with vildagliptin in patients with type 2 diabetes (T2DM)
Dejager, Sylvie
Lebeaut, Alexandre
Couturier, Andre
Schweizer, Anja
DIABETES, 2006, 55 : A29 - A29
[26] Saxagliptin (SAXA) Reduces A1C and Is Well Tolerated in Patients With Type 2 Diabetes (T2DM) and Albuminuria
Bonora, Enzo
Cook, William
Bryzinski, Brian
Hirshberg, Boaz
Allen, Elsie
DIABETES, 2013, 62 : A669 - A669
[27] Perception, HbA1c and the Quality of Life of Diabetes Mellitus (T2DM) Patients at RSUD Abdul Azis Singkawang
Faridah, Imaniar Noor
Masyithah, Nurul
Perwitasari, Dyah Aryani
ADVANCED SCIENCE LETTERS, 2017, 23 (12) : 12464 - 12468
[28] Rosiglitazone (RSG) is safe and well tolerated as monotherapy or combination therapy in patients with type 2 diabetes mellitus (T2DM)
Kreider, M
Miller, E
Patel, J
DIABETES, 1999, 48 : A117 - A117
[29] GLYCATED HEMOGLOBIN (HBA1C) CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) TREATED WITH CANAGLIFLOZIN IN A REAL-WORLD SETTING
Lefebvre, P.
Pilon, D.
Robitaille, M.
Lafeuille, M.
Chow, W.
Pfeifer, M.
Duh, M. S.
VALUE IN HEALTH, 2015, 18 (03) : A57 - A57
[30] TTP054, a Novel, Orally-Available Glucagon-like Peptide-1 (GLP-1) Agonist, Lowers HbA1c in Subjects with Type 2 Diabetes Mellitus (T2DM)
Gustavson, Stephanie
Grimes, Imogene
Valcarce, Carmen
Burstein, Aaron
Mjalli, Adnan
DIABETES, 2014, 63 : A41 - A42

← 1 2 3 4 5 →